STOCK TITAN

Elanco Animal Health - ELAN STOCK NEWS

Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.

Elanco Animal Health (ELAN) delivers innovative health solutions for pets and livestock worldwide. This dedicated news hub provides investors and industry professionals with essential updates on corporate developments, product innovations, and strategic initiatives shaping the animal health sector.

Access real-time press releases, earnings announcements, and regulatory filings alongside analysis of ELAN's advancements in veterinary pharmaceuticals. Our curated collection simplifies tracking of:

  • Quarterly financial results and investor communications
  • New product launches and FDA approvals
  • Strategic partnerships and R&D milestones
  • Industry leadership initiatives and sustainability efforts

Bookmark this page for streamlined access to verified ELAN updates. Combine our news feed with SEC filings and market analysis tools for comprehensive due diligence in the dynamic animal health market.

Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) is optimizing its manufacturing footprint post-acquisition of Bayer Animal Health by selling its Shawnee, Kansas and Speke, UK sites to TriRx Pharmaceuticals. This includes a long-term supply agreement and the transfer of ~600 employees. The sale is expected to incur impairment charges of $245M to $305M in Q2 2021, impacting EPS guidance by $0.43 to $0.54. Elanco anticipates a reduction in annual capital expenditures by $25M to $30M while expecting gross margins to reach 60% by 2023. Additionally, operations in Brazil will be consolidated to enhance efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health has appointed Marcela A. Kirberger as the new general counsel and corporate secretary, effective June 22. Kirberger brings over 20 years of corporate legal experience, previously serving at Roche Diagnostics and other major firms. Her role will encompass all of Elanco’s legal functions. The company's CEO, Jeff Simmons, highlighted her extensive background in regulated and pharma sectors as a valuable asset. Kirberger is also an advocate for Indiana's life sciences industry and aims to make a positive impact on animal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary

Kindred Biosciences (NASDAQ: KIN) announced positive results from a pivotal study of KIND-030 for treating canine parvovirus. The trial showed a 100% survival rate in dogs treated with KIND-030 compared to 43% in the placebo group. This monoclonal antibody targets canine parvovirus, offering a single injection treatment that eliminates the need for costly hospitalization. The results indicate potential for both treatment and prevention of the disease, with submissions for regulatory approval expected soon. Parvovirus has a mortality rate up to 91% if untreated, making this a critical advancement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
none
Rhea-AI Summary

Elanco Animal Health Incorporated (NYSE: ELAN) has announced its participation in two upcoming investor conferences in June. Jeff Simmons, the president and CEO, will hold a fireside chat at the Stifel 2021 Virtual Jaws & Paws Conference on June 3 at 2:30 p.m. ET, lasting approximately 25 minutes. He will also present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10 at 9:40 a.m. ET for about 40 minutes. Both conferences will be virtual, with live webcasts accessible on Elanco's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
-
Rhea-AI Summary

Elanco Animal Health has launched ZoaShield™ in the U.S., a solution for poultry producers to manage coccidiosis effectively. This new product features a proven active ingredient, zoalene, which is vital for maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks. Elanco emphasizes that ZoaShield offers producers flexibility to suit various operational needs and seasons. Additionally, the company provides consultative support from experienced field experts, enhancing operational efficiency for poultry producers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary

Elanco Animal Health reported strong Q1 2021 results, achieving revenue of $1,242 million, a significant rise from previous guidance of $1,150 - $1,170 million. The addition of Bayer Animal Health contributed $559 million to revenue. Adjusted EPS was $0.37, exceeding expectations. Pet Health revenue surged 213%, while global Seresto sales declined by 9%. Operating expenses were lower than anticipated, enabling Elanco to raise its 2021 guidance for revenue and adjusted EBITDA. The company expects eight product launches to drive future revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.89%
Tags
none
Rhea-AI Summary

Elanco Animal Health has launched Credelio Cat, the first oral flea and tick control product for cats, approved by the FDA. This chewable treatment starts killing fleas within 6 hours and provides protection against black-legged ticks for a month. Designed for cats 8 weeks and older, Credelio Cat is palatable and has a high success rate in administration, with 99.5% of owners successfully giving it to their cats. The product joins Elanco's extensive pet health portfolio, addressing a significant market need for effective oral parasite prevention in cats.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary

On April 28, 2021, Kindred Biosciences (NASDAQ: KIN) announced that the USDA has accepted the efficacy data for its monoclonal antibody, KIND-030, aimed at preventing canine parvovirus (CPV) infection. The pivotal study showed that 0% of treated dogs developed CPV, while the placebo group had a 100% infection rate. This acceptance is a significant milestone, progressing KindredBio's drug development for pets. The company expects to complete the efficacy study for treating established CPV by mid-2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Elanco has partnered with Ducks Unlimited to enhance environmental sustainability in beef cattle production across North America. From 2021 to 2023, Elanco will invest $50,000 annually to purchase grass seed for reseeding projects in western Kansas, aiming to restore 1,000 acres through the SAFE initiative. This collaboration aligns with Elanco’s sustainability framework, Healthy Purpose. Additionally, the announcement coincides with the launch of Experior™, a product approved by the FDA to reduce ammonia emissions from cattle waste, underscoring Elanco's commitment to sustainable agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
partnership
Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) will announce its first quarter 2021 financial results on May 7, 2021. A conference call will follow at 8:00 a.m. ET, accessible to investors, media, and the public via a webcast on Elanco’s website. This event aims to provide detailed insights into the company's performance during the quarter. Elanco is focused on innovating products to improve animal health, with nearly 70 years of experience in the industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags

FAQ

What is the current stock price of Elanco Animal Health (ELAN)?

The current stock price of Elanco Animal Health (ELAN) is $9.51 as of April 28, 2025.

What is the market cap of Elanco Animal Health (ELAN)?

The market cap of Elanco Animal Health (ELAN) is approximately 4.2B.
Elanco Animal Health

NYSE:ELAN

ELAN Rankings

ELAN Stock Data

4.21B
491.00M
0.88%
100.87%
2.92%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
GREENFIELD